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Abstract
Background Biosimilars are medicinal products that are
similar to a biopharmaceutical that has already been
authorised. As biopharmaceuticals are expected to dom-
inate the best-selling pharmaceuticals worldwide by
2016, the emergence of biosimilars imposes an important
challenge for governments. At this moment, the uptake
of biosimilars in Belgium is limited, with market shares
close to 0 %.
Objective This study aimed to identify the barriers that
impede the uptake of biosimilars in Belgium.
Methods Semi-structured interviews were conducted to
investigate in depth the barriers to the uptake of bio-
similars in Belgium. Respondents were selected through
selective sampling so that all different stakeholders
were represented (authorities, physicians, pharmacists,
patients, academics and industry). Respondents were
contacted by e-mail and letter with a request for par-
ticipation. A thematic framework was used to analyze
the data.
Results Three main barriers to the uptake of biosimilars
in the Belgian market were identified: a lack of confi-
dence towards biosimilars by some stakeholders; uncer-
tainty about the interchangeability and substitution of
biosimilars; and a hospital financing system that dis-
courages the use of them. Providing all stakeholders with
objective information on the concept of biosimilars,
reforming the financing of hospitals, developing and
implementing prescription quota in hospitals, setting up
patient registries for biosimilars and speeding up the
pricing and reimbursement process of biosimilars are
suggested solutions to increase the uptake of biosimilars
in Belgium.
Conclusions To fully capture the potential savings of
biosimilars, governments should take measures to
increase their uptake. The Belgian government, and also
the manufacturers of biosimilars, should take measures to
reduce the uncertainties related to biosimilars and raise
confidence among prescribers. In addition, the financing
of hospitals should be reformed and incentives should be
developed to stimulate physicians to prescribe
biosimilars.
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Key Points for Decision Makers
Biopharmaceuticals are expected to dominate the
best-selling pharmaceuticals worldwide by 2016
The emergence of biosimilars, which are similar to a
biopharmaceutical that has already been authorised,
imposes an important challenge for governments
Uncertainties surrounding biosimilars, resulting in
impaired confidence by physicians and patients, are
an important barrier to the uptake of biosimilars
To increase the uptake of biosimilars, governments
and companies producing biosimilars should inform
all stakeholders on the concept of biosimilars to
reduce the uncertainties
Incentives to prescribe biosimilars should be
developed as physicians are unlikely to change their
prescribing behavior without them
1 Introduction
The importance of biotechnological medicines or bio-
pharmaceuticals has increased over the past decade, with
worldwide sales almost doubling from US$63.8 billion in
2006 to US$124.6 billion in 2012 [1, 2]. By 2016, bio-
pharmaceuticals are expected to dominate the top ten of the
best-selling pharmaceuticals worldwide by seven out of ten
[3]. The expiration of data protection and patents on the
first biopharmaceuticals have opened up the market for
copy versions, so-called similar biological medicinal pro-
ducts or biosimilars, previously also known as follow-on
biologics in the US.
Biopharmaceuticals are produced out of cultures of living
cells and therefore are more complex molecules than small,
chemically synthesized medicines. The complexities in their
manufacturing process (e.g. type of expression system,
growth conditions, purification process, actual formulation,
conditions during storage and transport, etc.) also make it
impossible to produce identical products [4–6]. Different
batches of the same originator biopharmaceutical may even
have a certain degree of variability [7]. The complexity of
these products made the development of a specific regulatory
pathway for biosimilars necessary (i.e. legal framework,
general and product-specific guidelines or guidance), as that
of generic medicines seemed to be insufficient.
The European Commission was at the forefront of the
development of a specific regulatory pathway for biosim-
ilars and introduced a legal framework in 2003, the so-
called ‘biosimilar pathway’ [8–10]. A biosimilar is defined
by the European Medicines Agency (EMA) as ‘‘a product
which is similar to a biological medicine that has already
been authorized, the so-called ‘reference medicinal prod-
uct’. The active substance of a similar biological medicinal
product is a known biological active substance and similar
to the one of the reference medicinal product.’’ [11]. Unlike
generic medicines, biosimilars do not have to be strictly
identical to their originator equivalents and thus may have
a certain degree of variability, as defined in the guidelines.
Similar to all biotechnology-derived medicinal products in
the EU, biosimilars are, by law, reviewed centrally by the
EMA. Both general and product-specific guidelines have
been released by the EMA to assist and guide applicants
through the registration procedure.
In the US, a legal framework for biosimilars was only
introduced in 2012 by the Biologics Price Competition and
Innovation Act (BPCIA). This act introduced an abbreviated
approval process for follow-on biologic products in the US
(i.e. Abbreviated Biologics License Application, or ABLA),
which was previously missing [10, 12]. Biosimilar or bio-
similarity has been defined in the US to mean that ‘‘the
biological product is highly similar to the reference product
notwithstanding minor differences in clinically inactive
components,’’ and that ‘‘there are no clinically meaningful
differences between the biological product and the reference
product in terms of the safety, purity, and potency of the
product’’ [13]. Despite the legal framework, there is still
work to be done as in 2012 only four biosimilar implemen-
tation guidelines have been released by the US FDA [14].
Biosimilars in both the EU and the US have to dem-
onstrate comparable quality, safety, efficacy, and tolera-
bility (i.e. risk on immunogenicity) of the biosimilar
compared with the reference product. Applicants may
therefore partly rely on clinical data of the reference
product but still have to perform clinical trials, albeit not as
extensive as the reference product, to ensure that small
differences do not affect the clinical profile of the medi-
cine. Just like the reference biopharmaceutical, biosimilar
applicants are required to provide a risk management or
pharmacovigilance plan, taking into account potential risks
[6, 9, 15]. This is in great contrast with generic medicines,
which only have to demonstrate pharmaceutical equiva-
lence (i.e. identical active substances) and bioequivalence
(i.e. comparable pharmacokinetics) and may rely on all
clinical safety and efficacy data of the originator medicine
[15, 16]. It is thus important to stress that biosimilars
should not be regarded simply as generic versions of bio-
pharmaceuticals, and therefore the use of the expression
‘bio-generic’ is inappropriate [4]. The regulatory pathways
governing biosimilars differ somewhat between the EU and
the US. The main differences are related to exclusivity
periods, consideration of substitution and interchangeabil-
ity, and necessity of postmarketing monitoring of risks
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[15]. This need to demonstrate interchangeability in the US
may become a major stumbling block for their registration
as it will likely require costly switch trials.
The development of a biosimilar is thus a more complex
time- and cost-consuming process than the development of
a generic medicine [3, 15]. The development cost of a
biosimilar, for instance, is estimated between US$75 mil-
lion and US$250 million, whereas this is only between
US$1 million and US$5 million for a generic medicine
[17, 18]. As a result, price differences between biosimilars
and their reference product are estimated to be only
between 15 and 30 %, whereas this can be as high as 80 %
for generic and originator medicines [15, 19, 20]. Bio-
similars, however, still attract the attention of governments
and health care payers. The high prices of treatment with
biopharmaceuticals and their enormous impact on phar-
maceutical budgets mean that biosimilars can contribute
considerably to containing expenditures on biopharma-
ceuticals as the percentually small price difference will add
up to large sums of money [21]. By 2020, for instance, 12
blockbuster biopharmaceuticals, with global sales worth
over US$67 billion, will be exposed to competition by
biosimilars [22]. A calculation of possible savings from
biosimilars in eight European countries estimated their
savings potential between €11.8 and 33.4 billion between
2007 and 2020 [20]. The experience with the first genera-
tion of biosimilars has shown that biosimilars have also
induced significant price reductions for innovator medi-
cines. This shows the importance for governments to
develop a coherent policy to stimulate the uptake of bio-
similars in order to increase patient access to more
affordable biopharmaceutical therapies while maintaining
high-quality standards, especially in times when there is
rising pressure on pharmaceutical expenditures.
The first biosimilars in the EU have received a mar-
keting authorization in 2006 and since then 14 biosimilars
have been approved by the EMA in three different product
classes: five erythropoiesis-stimulating agents (epoetins),
seven granulocyte-colony stimulating factors (filgrastims),
and two growth hormones (somatropin) [23, 24]. In June
2013, the Committee for Medicinal Products for Human
Use (CHMP) of the EMA adopted a positive opinion,
recommending the granting of a marketing authorization,
for the first two biosimilar monoclonal antibodies, which
have shown to be similar to infliximab [25]. In the US, no
biosimilar has been approved by the FDA to date. The lack
of a specific regulatory pathway for biosimilar medicines
has urged pharmaceutical companies to use other strate-
gies. Several off-patent versions of low-molecular-weight
heparins, insulin, glucagon, and human growth hormones
(somatropin) have been approved and marketed in the US
by an Abbreviated New Drug Application (ANDA), which
is the procedure for generic medicines [26]. Another
biopharmaceutical, Teva’s filgrastim (Tbo-Filgrastim),
which is similar to Amgen’s filgrastim (Neupogen), has
been approved and marketed by a Biologics License
Application (BLA), which is the procedure for original
biopharmaceuticals. In contrast, the same product has been
marketed by Teva in Europe as a biosimilar filgrastim
(Tevagrastim) [17].
In Belgium, only five biosimilars are currently on the
market (i.e. two epoetins, one somatropin, and two filg-
rastims) [24, 27]. Whereas the uptake of biosimilars by
volume in many European countries is well above 20 %,
the uptake in Belgium is close to 0 %, as explained below
[28–31]. The sales of biosimilars in Belgium are also
generated for only one active substance (i.e. somatropin),
despite the presence of biosimilars in three different
product classes [24].
Previous research has shown that the choice of a phy-
sician to make use of a new innovation (i.e. a biosimilar in
this case) is determined by five key innovation criteria:
relative advantage (i.e. the degree to which an innovation is
perceived as better than its predecessor); compatibility (i.e.
the degree to which an innovation is perceived as being
consistent with the existing values, past experiences, and
needs of potential adopters); complexity (i.e. the degree to
which an innovation is perceived as being difficult to use);
trialability (i.e. the degree to which an innovation may be
experimented with on a limited basis before adoption), and
observability (i.e. the degree to which the results of an
innovation are observable to others). Meeting these adop-
tion criteria could positively influence the future success of
the development of biosimilars [32]. This also offers a
theoretical framework to evaluate the situation in Belgium
and which actions can be taken to improve the uptake of
biosimilars in Belgium.
The aim of this study was to identify barriers to the
uptake of biosimilars in Belgium. Possible solutions to
increase the uptake of biosimilars in Belgium are suggested
at the end of the article.
2 Methods
This study used qualitative research methods as this would
enable researchers to investigate in depth the barriers to the
uptake of biosimilars in Belgium. Semi-structured inter-
views were used as they enable the interviewer to elaborate
on specific aspects or insights of the interviewee or when
certain aspects are unclear for the researcher.
2.1 Participants
A total of 74 persons were contacted by both e-mail and
letter to participate in this study. Respondents were
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identified through selective sampling so that all relevant
stakeholders were represented: authorities (sickness funds,
regulator, members of the Belgian Drug Reimbursement
Committee); physicians; pharmacists; patients (i.e. patient
organizations); academics; industry originator; industry
biosimilar; and industry combined. Only stakeholders with
supposed experience with biopharmaceuticals were con-
tacted for participation.
2.2 Data Collection
Semi-structured interviews were conducted during the
period October 2012–February 2013 by a group of five
pharmacy students supervised by SS and PD. Respondents
who indicated they were willing to participate in the
interviews were contacted by e-mail for further arrange-
ments concerning time and place of the interview. If
requested by the interviewee, the semi-structured interview
guide was sent in preparation of the interview.
A semi-structured interview guide was drafted based on
topics derived from a literature review that was part of a
previous project of the group of five pharmacy students
(see electronic supplementary material). Three experts on
biosimilars were given the opportunity to comment on the
content validity of this semi-structured interview guide,
after which it was adapted according to their comments.
The respondents participated voluntarily and were not
remunerated. No approval from a research ethics commit-
tee was required because of the nature of the interviews.
The purpose of the study was explained at the beginning of
the interview, while the anonymity of participants and
confidentiality of the answers were guaranteed. The inter-
views were digitally recorded to facilitate the processing of
the results afterwards.
The interview started with some general questions about
the role of the interviewee and their knowledge on bio-
similars. Further on, different topics were discussed, such
as the development, registration, pricing, reimbursement,
prescribing, and dispensing of biosimilars in Belgium.
According to the characteristics of the interviewee, some
aspects were skipped while other aspects were more elab-
orated on.
2.3 Data Analysis
The interviews were analyzed according to the five stages
of the framework analysis described by Pope and Mays
[33]: (i) familiarization (reading of the transcripts and
notes, listening to the digital recordings); (ii) identifying a
framework; (iii) indexing (application of the framework to
the data); (iv) charting; and (v) mapping and interpreting.
As there was already a certain understanding of the issue in
advance of the analysis, a thematic framework was used. A
thematic framework was built by the students involved in
the study, based on previously identified main issues as
well as issues emerging from the data. The interviews were
analyzed using the software QSR NVivo 9 to facilitate the
analysis [34].
Two interviews were conducted in English, therefore no
translation of those quotes was needed. The selected quotes
of the other interviewees were translated as accurate as
possible.
3 Results
In total, 22 of 74 persons responded to our e-mail or letter
to participate in the study. Three persons ultimately deci-
ded to dropout after receipt of the interview guide: one
person due to a lack of expertise on the topic; one person
because of doubts about the added value of the interview
for the study; and one person because of a lack of time.
This resulted in 19 persons participating in the interviews.
All categories of stakeholders were represented and par-
ticipants were coded according to their function, as shown
in Table 1.
3.1 Lack of Confidence Towards Biosimilars
All interviewees acknowledged that a lack of confidence in
biosimilars by some stakeholders is one of the main bar-
riers to the uptake of biosimilars in Belgium. This lack of
confidence was most pronounced by physicians and rep-
resentatives of the originator industry, who tended to
question biosimilars on different aspects such as quality,
safety, and interchangeability.
‘‘The perceptions of biosimilars in general, whether
or not sustained by the originator industry, are: is the
Table 1 Classification of interviewees according to their function
(number of interviewees)
Interviewee Professional function
Aut (1–4) Authority
Aut 1: Representative of sickness funds
Aut 2: Regulator
Aut 3–4: Member of Belgian Drug Reimbursement Committee
Aca (1–3) Academic
IO (1–2) Industry originator
Phy (1–2) Physicians
Pha (1–3) Pharmacist
Pat (1) Patient
IB (1–3) Industry biosimilar
IOB (1) Industry combined
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quality of biosimilars sufficient, are these products of
equal quality?’’ (Aut4).
‘‘For biosimilars, there is a similar reluctance among
physicians. In the sense that we can have doubts
about whether or not they are identical to the parent
product. And there is still fear of a wider quality
tolerance for biosimilars, because the production
process is much more complex of course.’’ (Phy1)
Most interviewees acknowledged their trust in the
EMA and their registration procedures, except some
physicians who tended to distrust the EMA and their
procedures for biosimilars. Product-specific guidelines for
biosimilars were seen as a positive point by all stake-
holders. A possible need for even more specific and clear
guidelines, however, was voiced by representatives of the
authorities.
‘‘I think it’s helpful for the companies developing
medicinal products, for them to have also specific
guidelines. Because the companies actually like the
guidelines, in my experience …’ (Aca1)
‘‘So you have so many different types of biologicals:
blood factors, monoclonal antibodies, proteins,
enzymes, etc., which of course must be adapted to the
needs of the scientific guidelines and the scientific
aspects …’’ (IO2)
‘‘Guidelines actually ensure that it is actually clear
for the companies what we need to do. And for the
government they know what they can expect.’’ (IB1)
‘‘We see the same questions coming back regularly.
There is a clearly need for more guidelines, also
product-specific guidelines’’ (Aut2).
Physicians’ lack of confidence in biosimilars could be
explained by a knowledge gap, which in turn may be
caused by an ‘information gap’. Whereas manufacturers of
the reference product spent large amounts of money on
marketing and informing physicians and patients on their
products, manufacturers of biosimilars generally do not
make those efforts. They have, however, acknowledged
this shortcoming and have said to be working on it:
‘‘… There is a huge lack of information for doctors
and pharmacists …’’ (IB3)
‘‘… The companies that market originator products
do their very best to convince physicians on the
weaknesses that biosimilars may have …’’ (Phy1).
‘‘… A biosimilar company has never visited me.
Never! I have never even been visited by a repre-
sentative of those companies.’’ (Phy2)
‘‘… We have a field force, which are working for
more than a year on informing physicians and
patients on biosimilars, in the broadest sense of the
word …’’ (IB2)
‘‘… It is also up to companies that have biosimilars to
come forward and to say: this is the concept …’’
(IB3)
The representatives of the biosimilar industry also
pointed out the ambiguous and insufficient data provided
on the website of the Belgian medicines agency (FAGG).
‘‘… If you look at the website of the Belgian medi-
cines agency, for instance, those texts are old, ten-
dentious and over-simplified, not in accordance with
the EMA anymore …’’ (IB1)
A lack of clinical data supporting safe and effective use
of biosimilars was highlighted as an important issue. Part
of the concept of biosimilars is their reliance on data of the
reference product for efficacy and safety. Biosimilars have
to demonstrate clinical equivalence with the reference
product for one indication, after which the safety and
efficacy can be extrapolated to other indications without
additional clinical trials. The approval of marketing
authorization by the EMA, however, should assure all
stakeholders on the validity this fact.
‘‘… I think there are few clinical studies on biosim-
ilars. This will be the main barrier for physicians to
start prescribing …’’ (Aut3)
‘‘… I believe there are hardly any clinical studies
around biosimilars. That is the main obstacle for the
doctors to begin prescribing …’’ (Pha3)
‘‘… One of the comments that were made by physi-
cians on existing products was: ‘we have no experi-
ence with those products’. So for the next generation
of biosimilars we have also placed studies in Bel-
gium, so there are also Phase II studies in Belgium
…’’ (IB3)
‘‘… We really look for the most sensitive ways to
demonstrate differences. Once this is assured,
extrapolation to other indications may be accepted
…’’ (Aut2).
Some physicians, however, said that this is unfair to
originator companies, who spent large amounts of money
on clinical trials.
3.2 Interchangeability and Substitution of Biosimilars
Interchangeability and substitution of biosimilars is another
important issue. To prevent the misuse of these concepts, it
is necessary to provide the correct definitions, which were
also provided to the interviewees. Interchangeability is an
intrinsic property of a product, based on proven full ther-
apeutic equivalence. There are two forms of interchange-
ability: (i) at the population level, meaning that both
products can be used for treatment for the same condition
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in the same population; and (ii) at the individual level,
which means that in an individual patient the product can
be alternated or switched. Interchangeability at the indi-
vidual level is a condition for substitution. Interchange-
ability may lead to switchability: changing the product (e.g.
from reference product to biosimilar or vice versa) in a
patient during the course of treatment. Substitution is an
act, the replacement at the individual patient level of a
medicinal product for a similar/therapeutically equivalent
product during the course of a treatment without the pre-
scriber’s consent, e.g. at the pharmacy level [35].
At the moment, national authorities in Europe bear the
responsibility on interchangeability and substitution of
biosimilars. One academic suggested this should be the
responsibility of the EMA as they possess and evaluated all
the data.
‘‘… Personally I think interchangeability should be at
the EMA. Because they have all the data, they have
analyzed it properly. How can you make a decision if
you don’t have all clinical data or you haven’t ana-
lyzed it? I mean, why should national authorities do
that again? …’’ (Aca1).
Most interviewees agreed that initiation of therapies
with biosimilars should be no problem. Switching between
the reference product and biosimilars for patients under
treatment could cause some problems.
‘‘… For growth hormones, for instance, a chronic
treatment of many years, I would not be an advocate
of switching. These are patients who need a thera-
peutic equilibrium …’’ (IB2)
‘‘… You shouldn’t switch old patients but only new
patients. Let’s make this clear: if someone receives
medicine A, you should continue this therapy with
medicine A. Don’t start with substitution for these
patients …’’ (Pat)
‘‘… the prescribing of biosimilars should, in princi-
ple, be restricted to naive patients, unless there is a
good reason for old patients to switch …’’ (Pha1)
‘‘… Patients should be able to continue their therapy
with the same biological, unless there is a good
therapeutic (no economic) reason to switch…’’ (IO1)
‘‘… it is best for a patient to stay on the same med-
icine as long as possible, especially with recombinant
medicines …’’ (Aca2)
Representatives of the biosimilar industry highlighted
that reference products also face interbatch differences,
which are comparable with those between the biosimilar
and the reference product.
‘‘… If you compare two batches of the same pro-
ducts, they also possess differences. These are not
identical, but a biosimilar may vary as much as the
batches of innovator products …’’ (IB2)
Some stakeholders even went so far as to question the
need for biosimilars in Belgium.
‘‘… For me, biosimilars are no necessity in Belgium
or in other countries with the same quality of life as
Belgium …’’ (IO2)
‘‘… We are not asking for biosimilars … If there is
already one product on the market which is good,
why would you need five? …’’ (Pat)
‘‘… Because the question is: is it necessary to
develop biosimilars? …’’ (Phy2)
3.3 Financial Incentives Against Biosimilars
Financial motives are another major barrier to the uptake of
biosimilars in Belgium. Reference biopharmaceuticals
have a higher reimbursement limit than lower-priced bio-
similars. Most biopharmaceuticals and biosimilars in Bel-
gium are only dispensed in the hospital. The financing of
hospitals in Belgium is partly dependent on profits gener-
ated by the hospital pharmacy. Manufacturers of originator
biopharmaceuticals generally tend to offer discounts,
which exceed the price difference of biosimilars, while
manufacturers of biosimilars generally do not tend to offer
discounts in Belgium. As these discounts are fully recov-
ered by the hospital, the dispensing of the reference bio-
pharmaceutical becomes financially attractive for the
hospitals, but not for the third-party payer, a fact that was
acknowledged by many of the interviewees.
‘‘… This illustrates the problem of a biosimilar. Even
if they offer great discounts, they are still not eligible
to be used in the hospital. And the hospital even has a
strong argument: why would we use a biosimilar,
with all its problems, if we can use an original at the
same cost with more discounts? …’’ (Aut1)
‘‘So it is not necessary that a generic is the cheapest
or a biosimilar is the cheapest.’’ (Pha2)
‘‘… So the hospital benefits from the use of the most
expensive products instead of the cheap product.
Because then they make more money …’’ (IB1)
‘‘How come biosimilars don’t work in Belgium?
Because originators offer large discounts. And why
should you, as a hospital, switch to biosimilars in that
case?’’ (IO2)
‘‘… The physician who works in hospital says: ok,
either I make the third-party payer pay or I make my
hospital pay. So it’s not easy …’’ (Aca3)
In addition to the discounts, manufacturers of reference
products offer additional benefits to hospitals, so-called
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‘fringe benefits’. These benefits include professorships,
sponsoring, additional services for physicians, patients, etc.
These benefits may result in loyalty of physicians to these
companies, thereby, consciously or not, influencing their
prescribing behavior.
‘‘… Second way of return on investment can be
anything: you can give a lower price but you can also
give money for research, sponsor a conference, pro-
vide free goods or set up a medical need or com-
passionate use program …’’ (Pha2)
‘‘… They invest in physicians and services, by
sponsoring research and providing grants and many
more things like that. If you take this away, you are
messing with the prescriber …’’ (IB2)
‘‘… We like to have a good collaboration with the
companies because it helps as many of those com-
panies provide scientific support …’’ (Phy1)
Another financial barrier, which might be less obvious,
is the additional costs related to the logistics of biosimilars.
Biopharmaceuticals are products with a relative short shelf-
life, regularly on cold chain, which need an appropriate
distribution and storage system. If hospitals have to stock
both the reference product and the biosimilar, this creates
extra logistic needs for this hospital, which can be costly.
‘‘Those are products which are distributed and stored
in small quantities. So that is a real challenge in terms
of logistics.’’ (IB2)
4 Discussion
The uptake of biosimilars in Belgium is almost non-exis-
tent and this study has identified three main barriers to the
uptake of biosimilars in the market: a lack of confidence
towards biosimilars by some stakeholders; uncertainty
about interchangeability and substitution of biosimilars;
and a hospital financing system that discourages the use of
biosimilars. Biosimilars can, however, for the healthcare
system as a whole, offer significant savings on pharma-
ceutical expenditures. Therefore, the Belgian government
should remove these barriers and implement a coherent
policy to stimulate the uptake of cheaper medicines, like
biosimilars.
The Belgian government has recognized the importance
of biosimilars to contain escalating pharmaceutical
expenditures and has already made some efforts in this
respect. For instance, a symposium on ‘‘The emergence of
biosimilars: which opportunities for patients and the health
insurance?’’ was organized in 2012 by politicians (mem-
bers of parliament, deputies and senators) to discuss vari-
ous important aspects related to biosimilars [36].
This study explored the barriers to the uptake of bio-
similars in Belgium; however, it was subject to some
limitations. The outcome of an interview is dependent on
the expertise of both the interviewer and the interviewee on
the topic of biosimilars. Moreover, the use of a pre-defined,
semi-structured interview guide can be limiting with
respect to the issues discussed. Despite these limitations,
the barriers that have been identified in this study are in
accordance with the conclusions of the Belgian Health
Care Knowledge Centre (KCE), which investigated the
state of play of biosimilars in Belgium [24]. The main
barriers to the uptake of biosimilars identified in that study
were grouped into two main categories: clinical barriers
related to the knowledge of and attitudes towards biosim-
ilars; and lack of financial incentives and other services for
hospitals, prescribers, and patients [24]. These results
correspond in part to the outcomes of a survey on good
practices for the market uptake of biosimilars in European
member states and European Economic Area (EEA)
countries. This survey was conducted in 2012 by the
European Generic medicines Association (EGA) within the
scope of the European Commission Project ‘Process on
Corporate Responsibility in the Field of Pharmaceuticals
Platform Access to Medicines in Europe – Working Group
Access and Uptake of Biosimilars’. The main barriers
identified in this survey were ‘general perception that
biosimilar medicines are inferior to innovators’; ‘lack of
incentives to prescribe/deliver biosimilar medicines’; ‘lack
of regulation’; and ‘reluctance by doctors to switch brands’
[37].
Looking back at the theoretic framework that determines
a physician’s choice to make use of a new innovation, a
biosimilar entails uncertainty for all five key innovation
criteria (relative advantage, compatibility, complexity,
trialability, and observability). The relative advantage of a
biosimilar is unclear, and it may even come at a higher cost
for the hospital. Compatibility may be low as there is no
past experience and the reference product fits the current
needs. Complexity is high as the concept of similarity is
difficult to understand for physicians and patients. Triala-
bility of a biosimilar is unclear as the individual subscriber
will not see an obvious benefit if the biosimilar is only used
in a few patients (to try). The observability is also unclear,
as biosimilars hardly offer ground-breaking research results
[32]. This uncertainty, combined with the affinity with the
reference product and the fact that physicians and patients
do not like hassle with their medicines, may explain the
reservation of Belgian physicians to prescribe biosimilars.
Without any real incentive, physicians are unlikely to
change their prescription behavior [38].
Scepticism towards biosimilars is a common barrier to
their uptake throughout Europe [24, 37]. Doubts on the
interchangeability of biosimilars and their originator
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equivalents only strengthen this feeling. Due to the com-
plexities in the development process of biopharmaceuti-
cals, it has become accepted that biosimilars will never be
completely identical to their reference products, and clin-
ical trials will be required to assess their safety and
effectiveness. However, clinical trials are unsuitable and
not sensitive enough to fully identify possible differences
in safety or effectiveness [21, 39]. Therefore, regulatory
agencies might be unlikely to allow substitution for these
pharmaceuticals, unless interchangeability has been dem-
onstrated in appropriate additional clinical trials [21].
Nonetheless, a recent meta-analysis found no evidence
from clinical trial data or postmarketing surveillance data
that switching between different biopharmaceuticals leads
to safety concerns [40]. In addition to doubts on inter-
changeability, biosimilars might also suffer from uncer-
tainty on the cost effectiveness at the time of assessment
for reimbursement. In the absence of demonstrated inter-
changeability, most health authorities tend to request real-
world data on the effectiveness of biopharmaceuticals. As
these data are not available at the time of submission,
biosimilars might be considered by health authorities for
coverage with evidence development or risk-sharing
agreements [41].
Several policies have already been implemented by the
Belgian government to increase the uptake of biosimilars,
albeit with only limited success so far. Since 2012, bio-
similars in Belgium have been included in low-cost pre-
scribing quotas in ambulatory care [24, 42]. However,
biosimilars, like biopharmaceuticals, are mainly prescribed
by specialist physicians in hospitals. As a result, the policy
has had only limited impact on the uptake of biosimilars in
Belgium.
Another policy was the integration of epoetins and
growth hormones in the lump-sum reimbursement of
pharmaceuticals in hospitals [24, 42]. This is an important
step as it recognizes biosimilars and may lead to inclusion
of biosimilars in hospital formularies. This policy is,
however, more a cost-containment policy as it is hard to
see how this would stimulate the uptake of biosimilar
epoetins. The policy might even have negative effects on
patients. Due to the enormous cost of therapy with epoe-
tins, it is questionable if the limited lump-sum reimburse-
ment will cover all costs. As a result, patients might not
receive the proper treatment or hospitalized patients might
be discharged, after which they come back for treatment in
day care, where the lump sum reimbursement does not
apply.
The Belgian government also changed the reimburse-
ment of biosimilars, which are now categorized in reim-
bursement category F [24, 42]. Pharmaceuticals in this
category receive a flat-rate reimbursement, which is gen-
erally calculated on the price of the originator reference
product. The reimbursement of a biosimilar might subse-
quently be even higher than the actual price, which might
provide a stimulus to use biosimilars. However, this gen-
erates no additional savings for third-party payers, as both
the reference product and the biosimilars have the same
cost. Additionally, when the biosimilar and the reference
product have the same price, there is no incentive to use the
biosimilar. It might even stimulate manufacturers to offer
higher discounts on the reference product to retain their
market share. This policy is generally understood to have
only a limited impact on the uptake of biosimilars.
European governments have already implemented a
variety of policies to increase the use of biosimilars, which
seem to have had better success than in Belgium, according
to the correspondent market shares [24, 42]. Prescription
quotas/targets for biosimilars have been implemented in
(regions of) several European countries (e.g. Denmark,
Germany, Hungary and Italy) [24, 37]. Automatic substi-
tution of the reference product by a biosimilar and pre-
scribing by international proprietary name for biosimilars
is only formally instituted in Romania and not in any other
European country. Automatic substitution of biosimilars
for other biosimilars is allowed in Germany for some
products on a short list of ‘bio-identicals’, i.e. if they are
produced by the same manufacturer with the same manu-
facturing process [9, 24, 37, 39]. Some European countries
have also implemented stand-alone policies to increase the
uptake of biosimilars. Norway, for instance, has blocked
reimbursement of the reference product of filgrastim
(Neupogen), unless its price is reduced to the reim-
bursement level of the biosimilar filgrastim (Tevagas-
trim), which is about 55 % lower. In Austria, an
electronic form of the positive list lists biosimilars as
alternatives to the reference products together with their
prices. A prescription budget should motivate physicians to
prescribe biosimilars in the Czech Republic [37]. Hun-
garian physicians are required to initiate treatment of new,
naive patients with biopharmaceuticals that can be, at most,
5 % more expensive than the cheapest available product [5,
19]. Previous research suggests that national policies,
which differ from country to country, will have an
important impact on the ultimate uptake of biosimilars.
Bocquet et al. [43] analyzed the uptake of biosimilar
granulocyte colony-stimulating factor in the EU-5 markets
(i.e. France, Germany, Italy, Spain, and UK) and concluded
that biosimilar uptake, which varies significantly between
these countries, is mainly dependent on the local regulatory
framework and not on their prices.
In the US, despite the FDA still developing guidelines
regarding biosimilars, some states are considering, or have
introduced, laws related to the restriction of substitution of
biosimilars at the retail pharmacy level [44]. These ‘bio-
similar laws’ stipulate the pharmacists can only substitute a
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biosimilar for originator products if the following
requirements are met: the FDA deems the biosimilar
‘interchangeable’ (which will be the case by definition, as
the FDA will not regard it as a biosimilar otherwise); the
pharmacist notifies the prescribing physicians and the
patient; and the pharmacist keeps a record of the switch for
a certain period. Physicians always have, however, the
possibility of preventing substitution by ticking a ‘do not
substitute’ box. Some states have already passed this kind
of law, while several others have declined [44–47]. This
article rounds off with some recommendations to increase
the uptake of biosimilars in Belgium.
5 Recommendations to Increase the Uptake
of Biosimilars in Belgium
The recommendations that are presented to increase the
uptake of biosimilars in Belgium are based on known
practices, described in the literature, which have shown to
work in other countries and could remove the identified
barriers to the uptake of biosimilars in Belgium.
5.1 Inform All Stakeholders on the Concept
of Biosimilars
A negative perception of biosimilars by stakeholders,
especially physicians, is a main barrier to their uptake. All
stakeholders should receive unbiased information from an
independent source on the scientific concept of biosimilars,
their registration procedures, and their safety and efficacy.
The Generics and Biosimilars Initiative (GaBi), which was
founded in 2008, aims to provide a platform for healthcare
professionals with scientifically sound, reliable, well-doc-
umented, and up-to-date information on generic and bio-
similar medicines [48].
5.2 Reform the Financing of Hospitals
The current financing system of hospitals is perverse for
the cheaper alternative as it works as an incentive to use the
pharmaceutical on which the hospital has the biggest profit
margin. As originator companies offer high discounts,
which exceed the price difference with the biosimilars, the
hospital has an apparent economic benefit to use the orig-
inator products, at the expense of the third-party payers and
society as a whole. This way of financing is non-trans-
parent and may lead to unfair competition.
From 1 July 2013 on, tendering for pharmaceuticals
used in the hospital setting has been obligatory in Belgium,
regardless of the amount of the assignment [24]. It is,
however, to be seen if this practice leads to increased
transparency on prices and other services, as the details of
these procedures have been available only for the con-
cerned parties and not for the governmental authorities.
5.3 Develop and Implement Prescription Quota
in Hospitals
Biosimilars have been included in the low-cost prescription
quota in ambulatory care. This policy does not affect pre-
scription behavior in hospitals, where most biopharma-
ceuticals and biosimilars are used, as the policy is limited
to ambulatory care. As it is not always easy in a hospital
setting to identify the physician responsible, it might be
better to set these quotas at the level of the hospital. These
quotas should be combined with financial rewards/penalties
if the predefined quotas are not met as there will be no
incentive to comply otherwise. These quota should apply in
particular to patients on chronic treatment, as the largest
controversy around switching patients between the refer-
ence product and a biosimilar exists for this group. How-
ever, this policy will only be effective if the discounts on
reference products do not exceed the rewards/penalties in
addition to the price of the biosimilar.
Some interviewees also suggested reversing the system
and implementing limits on high-cost prescribing. This
would not necessarily lead to an increased prescribing of
biosimilars but could cause a change of mentality as the
prescribing of low-cost medicines would become the
standard.
5.4 Set-Up Patient Registries for Biosimilars
Lack of data on the safe and effective use of biosimilars is
highlighted by physicians as a reason not to prescribe them.
As biosimilars do not need to provide the same amount of
clinical data as the reference product to obtain marketing
authorization, this leads to a vicious circle, which prevents
physicians from prescribing biosimilars. Patient registries
allow documenting all patient experiences from using
biosimilars. These data could break this vicious circle and
provide physicians with sufficient data on large numbers of
patients.
5.5 Speed Up the Pricing and Reimbursement Process
of Biosimilars
The Belgian pricing and reimbursement authorities gener-
ally ask for additional data on quality, safety, and efficacy
of biosimilars before deciding on pricing and reimburse-
ment of these products. The assessment of quality, safety,
and efficacy is, however, the responsibility of the EMA
during the marketing authorization application. This
‘double assessment’ seems redundant and delays the mar-
ket access of biosimilars.
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6 Conclusion
The emergence of biosimilars imposes an important chal-
lenge for governments. A lack of confidence towards bio-
similars by some stakeholders, uncertainty about the
interchangeability and substitution of biosimilars, and a
hospital financing system that discourages the use of bio-
similars appear to be the main reasons for the limited use of
biosimilars in Belgium. The government, and also the
manufacturers of biosimilars, should take measures to
reduce the uncertainties related to biosimilars and to raise
confidence. In addition, the financing of hospitals should be
reformed and incentives should be developed to stimulate
physicians to prescribe biosimilars.
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